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Background. New insights into the pathogenesis and treat-
ment of diabetic renal disease may emerge from recent advances
in proteomics using high-throughput mass spectrometry (MS)
of urine.
Methods. Using a combination of online capillary elec-
trophoresis (CE) and MS we evaluated urinary polypeptide
patterns in four groups of type 2 diabetic patients matched
for age, gender, and diabetes duration, including 20 normoal-
buminuric patients with and 20 without diabetic retinopathy,
20 microalbuminuric patients with diabetic retinopathy, and 18
macroalbuminuric patients with diabetic retinopathy. Further-
more, changes in urinary polypeptide patterns during treatment
with the angiotensin II receptor blocker (ARB) candesartan
were evaluated in the macroalbuminuric patients in a random-
ized double-blinded, cross-over trial where each patient re-
ceived treatment with placebo, candesartan 8, 16, and 32 mg
daily each for 2 months.
Results. Overall, 4551 different polypeptides were found in
the samples. Urinary polypeptide patterns were comparable in
normo- (with and without diabetic retinopathy) and microal-
buminuric patients, whereas distinct differences were found in
macroalbuminuric patients. Differences in urinary polypeptide
patterns between normo- and macroalbuminuric patients per-
mitted the establishment of a “diabetic renal damage” pattern
consisting of 113 polypeptides. Eleven of these polypeptides
had been sequenced and identified. Candesartan treatment in
macroalbuminuric patients significantly changed 15 of the 113
polypeptides in the diabetic renal damage pattern toward lev-
els in normoalbuminuric patients. Change in the diabetic renal
damage pattern was not candesartan dose-dependent but in-
dividual changes correlated with changes in urinary albumin
excretion at each dose level.
Conclusion. CE-MS serves as a fast and sensitive tool for
identification of biomarkers and urinary polypeptide patterns
specific for macroalbuminuric type 2 diabetic patients and may
be used to explore and monitor renoprotective effects of ARB.
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Diabetic nephropathy develops in 30% to 40% of type
2 diabetic patients and has become the single most com-
mon cause of end-stage renal disease (ESRD) in the
western world [1]. The disease is diagnosed clinically
when persistent macroalbuminuria (urinary albumin
excretion ≥ 300 mg/24 hours) develops in the pres-
ence of diabetic retinopathy [1]. Diabetic nephropathy
is characterized clinically by elevated blood pressure,
increasing proteinuria, and a progressive decline in
glomerular filtration rate (GFR) leading toward ESRD
and enhanced cardiovascular risk. One of the earliest
signs of diabetic nephropathy is microalbuminuria (uri-
nary albumin excretion between 30 and 300 mg/24 hours)
which often progress to diabetic nephropathy. Progres-
sion of disease from normo- to micro- and macroal-
buminuria represents a continuum of renal functional
damage and structural abnormalities. This includes in-
creased intraglomerular hydraulic pressure, size-, and
charge defects of the glomerular filtration barrier and
alterations in handling of proteins in tubular cells, which
all leads to the occurrence of proteins in the urine and a
decrease in renal function.
The renin-angiotensin-aldosterone system (RAAS) is
known to play a central role for both the development and
progression of diabetic renal disease and the beneficial
renoprotective effect of inhibition of the RAAS by an-
giotensin II receptor blockers (ARBs) has been demon-
strated in three landmark trials of type 2 diabetic patients
with micro- or macroalbuminuria [2–4]. In these trials the
renoprotective effects of ARBs went beyond their blood
pressure–lowering effects and were superior to conven-
tional non-RAAS inhibiting antihypertensive agents in
reducing albuminuria and postponing the composite end
points of doubling of serum creatinine, ESRD, and death.
Consequently, ARBs are now recommended as first-line
agents to prevent and treat diabetic nephropathy [5].
Effective strategies to prevent renal function loss
should aim at early detection and treatment of patients
at high risk of developing diabetic renal disease. Ele-
vated urinary albumin excretion within the normal or
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microalbuminuric range is currently the strongest marker
of diabetic nephropathy risk but more specific and sensi-
tive risk markers are needed to identify high-risk individ-
uals since renal function may be reduced already at onset
of microalbuminuria and some patients with microalbu-
minuria do not progress to overt diabetic nephropathy.
New analytic tools that allow rapid screening and accu-
rate protein identification in body fluids are now emerg-
ing within the field of proteomic science [6]. In particular
the online combination of a high efficient separation tech-
nology with mass spectrometry (MS) is suitable to get the
maximum of information and detect low-abundant pro-
teins. Recently capillary electrophoresis (CE) coupled via
electrospray ionization to a time-of-flight (TOF) MS has
been used to analyze patterns of diabetic [7], nondiabetic
renal disease in urine [8, 9], and dialysis fluids [10]. Fur-
thermore, this technique, utilizing maps of urinary pep-
tides and small proteins, also enables the detection of
nonrenal diseases [11].
The aim of the present study was to evaluate if CE cou-
pled to MS would permit the detection of differences in
the urinary polypeptide pattern between carefully char-
acterized normo-, micro-, and macroalbuminuric type 2
diabetic patients matched for age, gender, and diabetes
duration. Furthermore, we aimed to determine if changes
in the urinary polypeptide pattern could be detected in
patients with diabetic nephropathy during treatment with
the angiotensin II receptor antagonist candesartan.
STUDY DESIGN
The urinary polypeptide pattern was evaluated in four
groups of type 2 diabetic patients, including (1) 20 patients
with persistent normoalbuminuria (<30 mg/24 hours)
and no diabetic retinopathy, (2) 20 patients with normoal-
buminuria in the presence of diabetic retinopathy, (3)
20 patients with persistent microalbuminuria (≥30 mg/24
hours and <300 mg/24 hours, in at least two out of three
consecutive samples) and presence of diabetic retinopa-
thy, and (4) 18 patients with persistent macroalbuminuria
(≥300 mg/24 hours) in the presence of diabetic retinopa-
thy [1]. The four groups were matched for age, gender,
diabetes duration, body mass index (BMI), and arterial
blood pressure. All previous antihypertensive medication
was withdrawn at least 2 months prior to examination
in order to eliminate influence of antihypertensive treat-
ment on urinary polypeptide excretion. Patients were
stratified into the normo-, micro-, and macroalbumin-
uric groups based on the urinary albumin excretion rate
in at least three 24-hour urinary samples collected after
2 months’ withdrawal of any antihypertensive medica-
tion. Patients with clinical or laboratory evidence of non-
diabetic renal disease were excluded from the study.
Changes in the urinary polypeptide pattern upon in-
creasing doses of the angiotensin II receptor antagonist
candesartan were evaluated in the 18 macroalbuminuric
patients. These patients participated in a previous study
evaluating the antiproteinuric effect of increasing doses
of the angiotensin II receptor antagonist candesartan in
type 2 diabetic patients with macroalbuminuria [12]. This
study originally comprised 23 patients. However, five of
the patients were excluded from the present analysis since
they did not have diabetic retinopathy. The remaining 18
patients were all included in the present study and all had
diabetic retinopathy and thus fulfilled the clinical criteria
for diabetic nephropathy.
The study design has been described in details pre-
viously [12]. In short, the study was a randomized
double-blinded, cross-over trial including four treatment
periods each lasting 2 months. In random order, each
patient received treatment with placebo (dose 00), can-
desartan cilexetil 8 (dose 08), 16 (dose 16), and 32 (dose
32) mg once daily. Study end points, including urinary
polypeptide patterns were evaluated at the end of each
treatment period. During the study diuretics were given
to prevent edema. Among patients with normoalbu-
minuria, four patients without and three patients with
presence of diabetic retinopathy received diuretics with
a median (range) dose corresponding to 30 (30 to 60) mg
of long-acting furosemide in both groups. All patients
with micro- and macroalbuminuria were treated with di-
uretics corresponding to a median (range) dose of 40 mg
(30 to 160) daily of long-acting furosemide with no signif-
icant difference in dosage between the two groups. The
dose of diuretic was kept unchanged throughout the en-
tire study when the effect of candesartan was evaluated
in the macroalbuminuric patients.
Type 2 diabetes was diagnosed in patients treated by
diet alone or by diet combined with oral hypoglycemic
agents; in patients treated with insulin when BMI was
above normal (≥25 kg/m2 in women, ≥27 kg/m2 in men)
at the time of diagnosis and diabetes onset was after the
age of 40 years; or in patients treated with insulin when
BMI was normal and a glucagon-stimulated C peptide
value was equal to or above 0.60 pmol/L.
The local ethical committee approved the study, and
all patients gave their informed consent to participate.
The study was performed in accordance with the Helsinki
Declaration.
METHODS
During days of examination all patients met at 8:00
a.m. after an overnight fast at Steno Diabetes Cen-
ter. GFR was measured during a 4-hour clearance pe-
riod after a single intravenous injection of 51-chromium
etheylendiaminetetraacetic acid (51Cr-EDTA) (3.7 MBq)
[13, 14]. The results were standardized for 1.73 m2 body
surface area. During the clearance procedure patients
drank 200 mL of water per hour. Albuminuria was
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determined as the geometric mean of three consecu-
tive 24-hour urinary collections, completed immediately
before each visit. Arterial blood pressure was mea-
sured in the sitting position after at least 10 minutes
rest by a Hawksley random zero sphygmomanometer.
The mean value of three readings was used. From ve-
nous samples, serum potassium, sodium, creatinine, and
cholesterol concentrations were determined (Cobas Mira
Plus) (Roche, Montclair, NJ, USA) and hemoglobin
A1c (HbA1c) was measured by high-performance liquid
chromatography (HPLC) (normal range 4.1% to 6.4%)
(Variant) (Bio-Rad Laboratories, Hercules, CA, USA).
Diabetic retinopathy was assessed by fundus photogra-
phy after dilatation of the pupils and graded as nihil, sim-
plex, and proliferative diabetic retinopathy.
CE-MS analysis
Urine samples used for evaluation of polypeptide ex-
cretion by CE-MS were collected during the 4-hour pe-
riod of the clearance period from 8:00 a.m. to 12:00 noon.
Aliquots of the urine samples were stored at −20◦C. For
CE-MS analysis 2 mL of urine was applied. The sam-
ples were prepared as described in details elsewhere [9].
The CE-MS analysis was established as described previ-
ously [10] using a Beckman Coulter, P/ACE MDQ system
(Fullerton, CA, USA) equipped with a 90 cm, 75 lm inner
diameter bare-fused silica capillary coupled to a Mariner
TOF MS (Applied Biosystems, Framingham, MA, USA).
Under these conditions, the detection limit is between 1
and 10 fmol (as judged by standard polypeptides), corre-
sponding to approximately 0.1 to 1 ng of a 2000 D peptide
per mL of urine.
Sequencing of polypeptides and database search
For the identification of polypeptides tandem MS anal-
yses (MS/MS) were performed with a matrix-assisted
laser desorption/ionization TOF (MALDI-TOF-TOF)
MS (Ultraflex) (Bruker Daltonik, Bremen, Germany).
The complete CE run was performed under the same
conditions but spotted at the CE outlet onto the MALDI
target (one spot every 15 seconds). The matrix solution [5
mg/mL a-cyano-4-hydroxy cinnamic acid (CHC) in 50%
acetonitrile and 0.5% formic acid] was added as sheath
liquid at 1 lL/min. The target was subsequently examined
in MS mode for the polypeptides of interest, based on the
data for molecular weight of the discriminatory polypep-
tides identified in the CE-MS analyses. The sequences
were matched to the NCBI-protein library (PubMED
and BLAST) for matches to known proteins.
Statistics and data processing
MosaiquesVisu (available at www.proteomiques.com)
(Biomosaiques Software, Hannover, Germany), a soft-
ware solution that has been described in detail [9, 11] was
used to evaluate the acquired raw data files. It uses iso-
topic distribution as well as conjugated masses for charge
state determination of polypeptides. The peaks, repre-
senting identical molecules at different charge states, are
deconvoluted into a single mass. CE migration time was
normalized to a list of internal standard polypeptides and
amplitude (signal intensity) was normalized to the total
polypeptide signal. Consequently, differences in the total
rate of urinary protein excretion are not valued.
To avoid the interpretation of data not related to pep-
tides, exclusively singly charged masses were discarded;
hence, only peptide masses above 800 D (m/z >400 and
z ≥2) were accepted. The detected polypeptides from all
132 samples were deposited and matched in a Microsoft
Access database, allowing further analysis and compari-
son of individual samples with each other. Polypeptides
in different samples were considered identical, if the mass
deviation was less than 0.05% and the CE migration-time
deviation was less than 5 minutes.
Further analysis was performed by comparison of the
frequency and the mean amplitude of each polypep-
tide between the considered groups. The mean ampli-
tude serves as a measure of the abundance/concentration
of the molecules detected relative to the total amount
of protein. Amplitudes were log-transformed because of
their positively skewed distribution and are presented as
geometric mean with 95% CIs. Frequency was defined as
the occurrence related to the number of samples in the
group. A polypeptide was arbitrarily defined as “typical”
for one group, if the frequency was at least 0.7 (70%).
To establish a diabetic renal damage pattern with
polypeptides discriminating between patients with and
without diabetic nephropathy we compared the fre-
quency and mean amplitude of each polypeptide found in
the normo- and macroalbuminuric groups. Based on the
frequency a polypeptide was arbitrarily defined as a “dia-
betic renal damage” marker if the difference in frequency
between the macroalbuminuric (dose 00) and the nor-
moalbuminuric groups were at least 0.7 (increased or de-
creased), and if the P value was below 0.01 (Fisher’s exact
test). Based on the amplitude, a polypeptide was defined
as a “diabetic renal damage” marker if the mean ampli-
tude was at least twofold different between the macro-
and normoalbuminuric groups and if the P value was
below 0.01 (Student t test for unpaired data). Com-
parisons of mean amplitudes were only performed for
polypeptides present in the majority of patient (fre-
quency ≥ 0.6) of both the normo- and macroalbuminuric
groups.
The effect of treatment with candesartan on the fre-
quency and amplitude of polypeptides in the diabetic re-
nal damage pattern was evaluated in macroalbuminuric
patients by comparison of placebo (dose 00) versus can-
desartan 16 mg (dose 16). The 16 mg dose of candesartan
was chosen a priory for simplicity since it was previously
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Table 1. Baseline characteristics of 78 type 2 diabetic patients
Normoalbuminuria Normoalbuminuria Microalbuminuria Macroalbuminuria
without diabetic with diabetic with diabetic with diabetic
retinopathy retinopathy retinopathy retinopathy
(N = 20) (N = 20) (N = 20) (N = 18) P value
Age years 58 (2) 56 (1) 61 (2) 60 (1) NS
Male/female 13/7 17/3 17/3 15/3 NS
Diabetes duration years 11 (2) 11 (1) 16 (2) 13 (2) NS
Office blood pressure mm Hg
Systolic 144 (3) 143 (3) 142 (4) 152 (4) NS
Diastolic 83 (2) 83 (2) 79 (2) 86 (2) NS
Glomerular filtration rate mL/min/1.73 m2 94 (3) 100 (3) 97 (4) 78 (2) <0.001
Hemoglobin A1c% 8.5 (0.3) 8.0 (0.2) 8.7 (0.3) 8.5 (0.3) NS
Data are mean (SE).
found to be the optimal dose for reduction of albuminuria
[12]. McNemar’s test and Student t test for paired data
were used to evaluate changes in frequencies and ampli-
tudes, respectively. A P value below 0.05 was considered
statistically significant.
For monitoring of the candesartan treatment the de-
fined diabetic renal damage pattern was compared with
the individual samples of the different dose levels. A pat-
tern recognition algorithm was used that calculates a con-
cordance factor by adding or subtracting an individual
value for one polypeptide whichever it is found in a sam-
ples above a distinct amplitude level or not. The calcu-
lated factor is expressed in percentage of the possible
congruence.
Comparisons of all clinical end points, including al-
buminuria, blood pressure and GFR, between each
treatment period were performed using linear mixed
models. The software used was R version 1.5.1 [http://
www.r-project.org]. The adapted model was one with
fixed effects of treatment level (placebo and candesar-
tan 8, 16, and 32 mg daily), visit (1, 2, 3, and 4), and
carryover (i.e., treatment level in the previous period),
and a random effect of person included to account for
the person dependencies in data. Tests for presence of
effects were performed as likelihood ratio tests, and fi-
nal estimates were reported as restricted maximum like-
lihood (REML) estimates. Values for albuminuria were
log transformed due because of their positively skewed
distribution.
RESULTS
Comparison of normo-, micro-, and macroalbuminuric
patients
Patients with normo-, micro-, and macroalbuminuria
were well-matched with respect to age, gender, dia-
betes duration, arterial blood pressure, BMI, and HbA1c,
whereas GFR was significantly lower in patients with
macroalbuminuria as compared to the other three groups
as shown in Table 1.
For CE-MS analysis each of the 132 samples was pro-
cessed individually. After CE-MS measurement, the ac-
quired raw data, displaying the mass-to-charge signals
over the migration time, were analyzed and subsequently
deconvoluted into a protein map with polypeptide mass
over normalized migration time as described in Figure 1.
Next the polypeptide information of all 132 samples was
collected in a database. Overall, 4551 different polypep-
tides were found in the samples. Many of these polypep-
tides occurred only in one or a few samples and they
appear not to contain information relevant for this study.
As a consequence and to reduce the amount of data, only
“relevant peptides” (peptides that appear in at more than
half of the patients in at least one of the different pa-
tient groups) were examined further. This reduced the
number of polypeptides to 758. The median number of
relevant urinary polypeptides was 523 in normoalbumin-
uric patients without diabetic retinopathy, 580 in nor-
moalbuminuric patients with diabetic retinopathy, 639 in
microalbuminuric patients, and 507 in macroalbuminuric
patients.
Polypeptide maps typical for patients with normo-,
micro-, and macroalbuminuria are shown in Figure 2.
These four maps consist of all polypeptides with a fre-
quency of occurrence of at least 0.7 within the respective
four groups. As evident from the figure, patients with
normoalbuminuria (with and without diabetic retinopa-
thy) and patients with microalbuminuria had compara-
ble polypeptide maps. In contrast, the polypeptide map
in patients with macroalbuminuria was clearly different
with the appearance of larger molecules with shorter mi-
gration times (equal to higher net charges and increased
cross-sectional area of the polypeptides). In addition the
number of typical polypeptides decreased from about
250 in normo- and microalbuminuric patients to 140 in
macroalbuminuric patients.
Similarly, maps were created showing group specific
polypeptides (Fig. 3). Here, all polypeptides are displayed
with a frequency of occurrence of at least 0.7 in patients
within one group and with lower frequencies in the other
groups. Again, distinct polypeptides with short migration
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Fig. 1. Each sample is initially processed individually by the MosaiquesVisu software. To ease examination by eye, the acquired raw-data are
converted into a plot displaying the mass/charge-ratio against the capillary electrophoresis (CE) migration time (top panels). The data are further
evaluated by MosaiquesVisu and only those signals are accepted that fit the criteria of “real signal”: present in at least three consecutive spectra
with a signal-to-noise ratios of > 7 (middle panel). The software deconvolutes the signals by computation of isotopic distribution and allocation
of conjugated masses, which results in a spectrum where normalized migration time is plotted against mass (bottom panel). The information of
polypeptide masses, CE migration times and amplitudes of all 132 individual samples were collected in a database for peak matching. This enables
the generation of compiled patterns and the comparison of group specific frequency, amplitudes and probabilities (bottom right).
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Fig. 2. Typical polypeptides in normo-, micro-, and macroalbuminuric patients. Polypeptides with frequencies of occurrence greater than 70% in
each individual group are displayed with their mass over the migration time. A total of 231 polypeptides were classified as typical for normoalbu-
minuric patients without diabetic retinopathy (top left panel), 266 for normoalbuminuric patients with diabetic retinopathy (top right panel) and
256 for microalbuminuric patients with retinopathy (bottom left panel). While these patterns appear quite similar, some of the 140 polypeptides
classified as typical for macroalbuminuria (bottom right panel) show a different migration time behavior and are of higher molecular mass.
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Fig. 3. Group-specific polypeptides. Specific
polypeptides were defined for each group
(normoalbumin, microalbumin, macroalbu-
min). The 136 normo-specific polypeptides
were found in at least 70% of the normoal-
buminuric samples and in less than 30%
of the macroalbuminuric patients. In con-
trast 59 polypeptides were found in ≥70%
macroalbuminuric and in <30% normoalbu-
minuric samples. In addition 11 polypeptides
were defined as specific for the microalbumin-
uric group (≥70% micro, <30% normo, and
<30% macro).
times appear to be specific for the macroalbuminuric
patients.
To depict the state of “diabetic renal damage,” a pat-
tern was created that consists of 113 polypeptides with
significant differences between patients with macroalbu-
minuria and those with normoalbuminuria (Fig. 4). The
pattern comprises polypeptides that occur either more
or less frequently in patients with macroalbuminuria or
polypeptides with increased or decreased mean ampli-
tude (counts) as defined previously. For this pattern, 27
polypeptides were found with an increase in the fre-
quency of occurrence of at least 0.7 from the normo-
to the macroalbuminuric group. On the other hand 55
polypeptides were included with a decrease in the fre-
quency of occurrence of at least 0.7. Five polypeptides
were found with a mean amplitude that was more than
twofold higher in macroalbuminuric patients whereas 26
polypeptides were found with an amplitude which was
twofolder lower in patients with macroalbuminuria as
compared to normoalbuminuric patients. Polypeptides
that differed in either frequency or amplitude between
the normo- and macroalbuminuric groups all had P val-
ues below 0.01.
Of the 113 polypeptides identified as diabetic re-
nal damage markers, 11 have presently been identified.
Among these are fragments of albumin, Tamm-Horsfall
protein, and collagen (Table 2).
Treatment effects by ARB in macroalbuminuric patients
Albuminuria was significantly reduced by all three
doses of candesartan. In comparison to placebo,
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Fig. 4. Diabetic renal damage marker
polypeptides. A total of 113 polypeptides
were found to be significant changed between
normo- and macroalbuminuric patients.
Fifty-five were reduced () and 27 were
increased (×) in frequency of occurrence by
at least 70%. Thirty-one polypeptides were
significantly altered in their amplitude, five
increased in mean at least twofold (+) and
26 decreased at least two fold (−). Fifteen of
the marker polypeptides were distinctively
changed by the candesartan treatment ().
Table 2. Polypeptides identified by mass spectrometry/mass spectrometry (MS/MS) fragmentation and sequence identification
Theoretic
Detected mass- Diabetic renal
mass D monoisotopic D Sequence Substance (peptide from) damage marker type Treatment change
1034, 50 1034, 59 LKSRVTMS Ig heavy chain Frequency positive
1061, 79 1061, 62 FKAWAVARL Human serum albumin Frequency positive
1182, 73 1182, 61 GEYKFQNALL Human serum albumin Frequency negative
1218, 51 1218, 64 PLGLPGIDGIPGL Collagen alpha 6 (IV) Amplitude negative
1298, 56 1298, 62 TYVPKEFNAET Human serum albumin Amplitude positive Amplitude reduced
1334, 72 1334, 65 EPGVSGPMGPRGPP Human collagen 1 (II) alpha Frequency positive Frequency reduced
1680, 91 1680, 90 VIDQSRVLNLGPITR Human uromodulin Amplitude negative
(Tamm-Horsefall)
1716, 06 1716, 99 VRYTKKVPQVSTPTL Human serum albumin Amplitude positive
1768, 01 1768, 00 SVIDQSRVLNLGPITR Human uromodulin Amplitude negative Amplitude increased
(Tamm-Horsefall)
2229, 23 2229,07 DAHKSEVAHRFKDLGEENF Human serum albumin Amplitude positive Amplitude reduced
2428, 19 2428,21 DAHKSEVAHRFKDLGEENFKA Human serum albumin Frequency positive
albuminuria was reduced by [mean difference (95%CI)]
35% (7% to 45%) during treatment with candesartan
8 mg daily, whereas candesartan 16 and 32 mg lowered
albuminuria by 60% (48% to 70%) and 56% (46% to
70%), respectively. The two highest doses were signif-
icantly more effective in reducing albuminuria as com-
pared to 8 mg without difference between candesartan
16 mg and 32 mg daily. Arterial blood pressure was re-
duced from 152 (4)/86 (2) mm Hg during placebo to 144
(5)/79 (2) mm Hg, 142 (5)/78 (2) mm Hg, and 141 (5)/78
(3) mm Hg during treatment and GFR was reduced from
78 (6) mL/min/1.73 m2 to 72 (6) mL/min/1.73 m2, 70 (6)
mL/min/1.73 m2, and 70 (5) mL/min/1.73 m2, respectively.
The reductions in both arterial blood pressure and GFR
during all three doses of candesartan were statistically sig-
nificant in comparison to placebo but without significant
differences between the three doses.
Fifteen of the 113 diabetic renal damage markers were
significantly changed upon treatment with candesartan
as emphasized by the circles in Figure 3. The observed
changes affect all types of diabetic renal damage markers,
positive as well as negative. Although the identification
of these 15 polypeptides was done by comparison of dose
00 (placebo) level to dose 16 (candesartan 16 mg daily),
treatment effects for these 15 polypeptides were compa-
rable for the other doses of candesartan as well (Fig. 5).
As shown in Table 3, all 15 diabetic renal damage mark-
ers were changed toward frequencies or mean amplitude
levels in normoalbuminuric patients.
We utilized the 113 polypeptides of the diabetic renal
damage pattern to monitor the treatment with candesar-
tan over the three different dose levels. A simple pattern
recognition algorithm was used that searches for polypep-
tides within a distinct time and mass window. Once it is
found above a certain counts level, a value describing the
difference between healthy and disease for this polypep-
tide is added to a total factor, otherwise it is subtracted.
Figure 6 describes the results of this algorithm for one of
the observed patients. The detection of “positive” mark-
ers, defined by an increased occurrence in the macroal-
buminuric group, considerably decreases when treatment
with candesartan is applied. At the same time the de-
tection of “negative” markers, which are polypeptides
specific for the pattern in normoalbuminuric patients, in-
creases slightly. As a result, the overall factor, represent-
ing the total proteome pattern recognition for a diabetic
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Fig. 5. Significant changes in polypeptide frequency and amplitude by
candesartan treatment in type 2 diabetic patients with macroalbumin-
uria. Fifteen polypeptides from the list of diabetic renal damage marker
were found to be significant changed during treatment with candesartan
either in frequency of occurrence (upper panel) or in amplitude (lower
panel). All amplitudes are expressed on a log scale as geometric mean
with bars representing the 95% CI.
renal damage, decreases from 86% to 54%, indicating a
profit by the treatment. All individual changes in the di-
abetic renal damage pattern match upon treatment with
candesartan are shown in Table 4. Using linear regression
analysis, individual changes in the diabetic renal damage
pattern match were found to correlate significantly with
changes 24-hour urinary albumin excretion rate at each
dose level. Figure 7 shows the positive correlation be-
tween individual changes in the diabetic renal damage
pattern match and changes in 24-hour urinary albumin
excretion rate during treatment with candesartan 16 mg
versus placebo, indicating that the greater the decline in
diabetic renal damage pattern match, the greater the de-
cline in albuminuria (R2 0.27).
DISCUSSION
In our study we used the online-combination of CE
and electrospray MS to establish urinary polypeptide pat-
terns in well characterized type 2 diabetic patients with
normo-, micro-, and macroalbuminuria. Our study re-
vealed distinct differences in the urinary polypeptide pat-
terns between normo- and macroalbuminuric patients,
whereas normo- and microalbuminuric patients had com-
parable urinary polypeptide patterns. Differences in
urinary polypeptides patterns between normo- and
macroalbuminuric patients were used to generate a dia-
betic renal damage pattern. Among the 113 polypeptides
included in the diabetic renal damage pattern eleven were
identified by a CE target spotter and an offline combi-
nation to MALDI MS/MS, these included fragments of
albumin, Tamm-Horsfall protein, esterase, and collagen.
Among patients with macroalbuminuria we found signifi-
cant changes upon treatment with candesartan in 15 of the
113 polypeptides included in the diabetic renal damage
pattern, all toward levels in normoalbuminuric patients.
MS-based clinical proteomics is an increasing field for
the early detection of diseases and diagnosis of an or-
ganism’s state of health. Many different technologies are
established to find, monitor, and document pathologic
changes in the proteome [15]. The online combination of
CE and electrospray MS applied in the present study was
recently developed for the fast, sensitive, and automated
measurement of different body fluids [8, 9, 16]. Using this
technology in a recent study we could demonstrate that
CE-MS could be used to discriminate healthy individuals
from patients suffering from various forms of nondiabetic
renal disease based on their urinary polypeptide patterns
[9]. Furthermore, it has been demonstrated that CE-MS
analysis of urinary polypeptide patterns may be used to
differentiate between minimal change disease and focal
segmental glomerulosclerosis [8].
An obvious limitation of the CE-MS technology is the
fact that generally proteins above approximately 20 kD
cannot be analyzed with sufficient reproducibility. This
is due mainly to poor solubility of these proteins in the
buffer used for CE. On the other hand, there is evi-
dently a high information content in the smaller polypep-
tides which are easily accessible using the CE-MS tech-
nology. To further improve the reproducibility of the
CE-MS analysis, it might actually be beneficial to re-
move the larger proteins which appear not contain too
much accessible information and actually might obscure
the analysis of the smaller polypeptides with potential
pathophysiologic importance.
An approach that has recently been used by several
laboratories for the examination of polypeptides in hu-
man body fluids is the SELDI-TOF technology. However,
it appears that the SELDI technology currently has sev-
eral severe limitations which also led to an intense dis-
cussion of the application of proteomics toward clinically
relevant questions [17–19]. In a recent comparison of CE-
MS and SELDI-TOF, the limitations of the SELDI-TOF
technology became evident [20]. Among these are the
high matrix and concentration dependency of the SELDI
results, the poor mass accuracy, a lack of comparability
due to the use of different surfaces in different labora-
tories and the inability to easily obtain sequence of the
potential biomarkers. Our results suggest that if an
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Fig. 6. Polypeptide pattern recognition for monitoring of therapeutic
effects. The list of 113 diabetic renal damage marker polypeptides was
applied to the samples undergoing candesartan treatment. A pattern
recognition algorithm (DiaPat) was used to specify the analogy between
the sample pattern and the marker list (first bar). Since the marker list is
composed of positive (present/increased in diabetic renal damage sam-
ples) and negative (absent/decreased in diabetic renal damage samples)
markers, both types are displayed in percent in the second bars and the
third bars. As a result of the treatment, the detection of “diabetic renal
damage positive markers” decreases in the samples of this patient from
74% to 15%, while the detection of “diabetic renal damage negative
markers” increases from 6% to 18%. The overall calculated factor for
diabetic renal damage decreases from 86% without treatment, to 74%
at dose level 8, 69% at dose level 16, and down to 54% at dose level 32.
Table 4. Effect on changes in diabetic renal damage pattern match of
increasing doses of candesartan in 18 type 2 diabetic patients with
macroalbuminuria
Treatment response
(change in diabetic renal damage pattern match)
Dose Dose Dose Dose Best
Patient 0 mg 8 mg 16 mg 32 mg change
1 77 42 43 67 −35
2 93 74 58 80 −35
3 77 50 43 67 −34
4 86 74 69 54 −32
5 82 60 79 53 −29
6 88 82 89 67 −21
7 90 70 70 69 −21
8 85 88 68 79 −17
9 83 71 70 88 −13
10 86 73 76 80 −13
11 91 91 79 89 −12
12 83 78 86 71 −12
13 87 76 80 82 −11
14 85 77 77 89 −8
15 81 81 74 81 −7
16 88 85 86 89 −3
17 85 91 86 84 −1
18 81 81 84 82 0
Mean 85 75a 73a 76a
aP < 0.01 versus placebo (dose 0 mg)
in depth investigation of larger proteins is required,
then two-dimensional-polyacrylamide gel elctrophoresis
(PAGE) might still be the best available method. How-
ever, this is a laborious and highly time-consuming pro-
cess which appears poorly suited for examination of a
large number of samples as often needed in the clin-
ical setting. In addition, it is highly likely that most
of the relevant information in urine can be found in
the smaller polypeptides, which are not accessible with
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Fig. 7. Correlation between change in diabetic renal damage pattern
match and change in albuminuria upon treatment with candesartan 16
mg daily as compared to placebo in 18 type 2 diabetic patients with
diabetic nephropathy.
two-dimensional-PAGE. For the investigation of these
smaller proteins and peptides, CE-MS appears to be a
better tool which allows the analysis of >1000 different
polypeptides within approximately 1 hour with high re-
producibility [21]
In our study, the diabetic renal damage pattern was
composed from polypeptides that differed in frequency of
occurrence or in amplitude (abundance) between normo-
and macroalbuminuric patients. When comparing this
pattern with the polypeptides within an unknown sam-
ple, a quantitative value is gained, that expresses the
accordance between patterns in normo- and macroalbu-
minuric diabetic patients and as a conclusion character-
izes the presence or absence of diabetic renal damage.
To establish the diabetic renal damage pattern we used
arbitrary cut-off points for differences in frequency
of occurrence and amplitudes between normo- and
macroalbuminuric patients. Presumably additional dis-
criminating polypeptides may exist and other polypeptide
patterns may potentially also be used to differentiate be-
tween patients with and without diabetic nephropathy. A
complete consideration of all involved proteins, however,
is not necessary in order to differentiate between normo-
and macroalbuminuric patients when using a polypeptide
pattern recognition approach. Furthermore, for diagnos-
tic purposes it is not required to have more knowledge
about the polypeptides used to define the disease pat-
tern than the fact that the occurrence or abundance is
altered by the disease. Neither the identity of one indi-
vidual marker, nor its function has to be known [22, 23].
The used technology of capillary electrophoreses online
coupled to an electrospray MS can easily be modified
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for identification of polypeptides. As demonstrated, the
electrospray ionization is replaced by a CE target spotter
and an offline combination to MALDI MS/MS is used
for fragmentation of polypeptides of interest while the
high efficient separation performance still maintains. Us-
ing such technique we successfully sequenced and iden-
tified 11 of the polypeptides in the diabetic renal damage
pattern.
Surprisingly, we found discrete fragments of abun-
dant proteins, and not, as initially expected, peptides
evenly distributed throughout the complete molecule.
This might in part be a result of diverse sensitivity to-
ward proteases. While certain regions in proteins might
be preferred targets to multiple protease cleavage or ex-
oproteases, resulting in the generation of multiple small
fragments (below 800 D) that are not detected by CE-
MS, other regions might be more resistant, hence discrete
higher molecular weight peptides are generated. Changes
in protease activity during the development of chronic
renal diseases have been described by others [24]. This
might also be reflected by our data.
Evidently, several of the peptides found in this study
are fragments of albumin and Tamm-Horsfall protein.
This is not unexpected since these proteins are abun-
dantly found in urine. Interestingly, in our study two
fragments from Tamm-Horsfall protein were found to
occur with decreased amplitudes among patients with
macroalbuminuria as compared to patients with normoal-
buminuria. This is in agreement with previous studies
using conventional immunohistochemical methods that
demonstrated reduced levels of Tamm-Horsfall protein in
patients with renal disease [25–27]. Tamm-Horsfall pro-
tein has been suggested to serve as an immunoregulatory
molecule in the kidney involved in the urothelial defense
against infections and to regulate the water permeabil-
ity in the thick ascending limb of Henle and the distal
tubular reabsorption of sodium [28]. Even more interest-
ingly, one of the fragments of Tamm-Horsfall protein was
found to increase in amplitude in a dose dependent level
upon treatment with candesartan toward levels in nor-
moalbuminuric patients. This may potentially represent
a new renoprotective pathway of ARB treatment in di-
abetic nephropathy, which needs confirmation in studies
using conventional immunohistochemical methods.
In contrast, not all fragments from albumin are found
to be increased in patients with diabetic renal damage,
in fact, some are even decreased. These observations
are probably best explained by changes (both increase
as well as decrease) of the activity of certain proteases.
This in turn would result in significant changes in the
abundance of the peptides generated by these proteases.
Hence, we currently interpret the changes in the urinary
polypeptides as an indirect measure of modified (prob-
ably both increased as well as decreased) protease ac-
tivity. Evidently, a more thorough investigation of these
proteases and their physiologic regulation is well justified
and should give additional insights into the pathophysi-
ology of chronic renal damage.
The appearance of polypeptides from high-molecular-
weight proteins supports the assumption that there is no
implied need to display the complete proteome for di-
agnostic purpose. The technical constituted limitation of
CE-MS to the low- and middle-molecular-weight pro-
teome up to about 20 kD allows the creation of diagnostic
polypeptide maps depleted from high abundant proteins,
while the information content still remains. Moreover, re-
cent studies demonstrate the importance of a differential
consideration of low-molecular-weight fragments of pro-
teins, especially albumin. In healthy kidneys of rodents
and humans, more than 90% of the filtered albumin is
fragmented into small peptides (<15 kD) within minutes
[29–32]. In the diseased kidney this pathway appears to be
impaired, leading to reduction of the fragmentation ratio
[32]. In addition, recently published studies demonstrate
that conventional immunoassays may underestimate al-
bumin concentration, particularly in urine from diabetic
patients, because of different, immunounreactive albu-
min isoforms [33, 34]. These results, together with the
observation that many different polypeptides from high-
molecular-weight proteins can be found in urine, indicate
that an unbiased proteome pattern approach may be op-
timal for marker discovery and diagnoses.
In our study, the urine polypeptide patterns from most
patients were significantly altered by treatment with the
ARB candesartan. The changes seen in the diabetic renal
damage pattern upon angiotensin II receptor treatment
represents a combined reduction of disease-specific and
an increase of normal-specific signals, thus converging to-
ward the polypeptide pattern seen in normoalbuminuric
patients. In the present study we reported data on the
15 polypeptides within the diabetic renal damage pattern
that changed upon treatment. However, other polypep-
tides not included in the diabetic renal damage pattern
were also changed upon treatment with candesartan. The
importance of such changes can not be established in the
present study where changes in the diabetic renal dam-
age pattern upon treatment correlated rather weakly with
changed in albuminuria, but would require a long-term
follow-up study where treatment effects are evaluated
by principal renal end-points such as doubling in serum
creatinine or development of ESRD. Likewise, a long-
term study would be needed to establish if CE-MS can
be used to identify urinary polypeptides in normoalbu-
minuric patients that predict subsequent development of
diabetic nephropathy.
In addition to the degree of diabetic renal disease and
antihypertensive treatment, many other factors are likely
to affect the urinary polypeptides excretion. In an at-
tempt to reduce the impact of confounding variables on
the urinary polypeptide patterns we used standardized
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procedures for collection, storage and handling of urine
samples. In addition we strived to carefully match normo-,
micro-, and macroalbuminuric patients for age, gender,
diabetes duration, and blood pressure level, which are
well known risk factors for development of diabetic re-
nal disease. We also withdrew previous antihypertensive
treatment at least 1 month before evaluation, thereby
avoiding potential influence of blood pressure–lowering
agents on polypeptide excretion and urinary albumin ex-
cretion when stratification of patients into the normo-,
micro-, and macroalbuminuric groups. Furthermore, the
effect of different doses of candesartan on the urinary
polypeptide pattern in macroalbuminuric patients was
carried out as a cross-over trial, which excludes in-
terindividual variations in the evaluation of changes in
the urinary polypeptide pattern upon treatment with
candesartan.
The present study clearly represents an early step to-
ward the implementation of proteomics in the clinical
setting. However, our study has demonstrated that CE-
MS serves as a fast and sensitive tool for identification of
biomarkers and urinary polypeptide patterns that can be
used to discriminate between diabetic patients with and
without diabetic nephropathy and furthermore to moni-
tor treatment effects. The data also indicate that several
potential biomarkers in addition to albumin can be de-
fined using CE-MS and, if required; MS/MS sequenced.
It is to be expected that these additional markers allow
a more thorough and accurate investigation and descrip-
tion of the renal function, consequently leading toward a
deeper understanding of the pathophysiology of diabetic
renal damage. In addition, it is to be hoped for that these
additional biomarkers will also enable improvements in
therapeutics and therapy. Thus CE-MS seems to have
great clinical potential in the future for prognostic and
differential diagnostic purposes for instance in charac-
terizing the heterogeneous nature of proteinuria in type
2 diabetic patients [35]. However, long-term studies are
needed in order to establish the role of CE-MS in terms of
predicting development and progression of diabetic renal
disease, and long-term effects of renoprotective therapy.
Reprint requests to Kasper Rossing, Steno Diabetes Center, Niels
Steensens Vej 2, Gentofte, Denmark.
E-mail: krossing@dadlnet.dk
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